Oncology · Clinical trials
Oesophageal Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About oesophageal cancer — and why its trials are hard
Oesophageal cancer comprises two biologically distinct main types: squamous cell carcinoma, dominant globally and linked to tobacco, alcohol and dietary factors, and adenocarcinoma, common in Western countries and associated with reflux, Barrett's oesophagus and obesity. Gastroesophageal junction (GEJ) tumors overlap with gastric cancer biology. Prognosis is often poor because most patients present with locally advanced or metastatic disease. Trials are hard for several reasons. Histologic and anatomic heterogeneity (squamous vs adenocarcinoma, oesophageal vs GEJ) means results may not generalize, requiring careful subgroup analysis. Dysphagia, weight loss and malnutrition impair performance status, tolerability and accrual. Biomarkers such as HER2, PD-L1 (CPS or TPS) and Claudin 18.2 stratify benefit and demand testing. Multimodality care (neoadjuvant chemoradiation, surgery, perioperative chemotherapy) complicates where a new agent fits and how to measure incremental benefit. Regional differences in standard therapy between Asia, Europe and North America affect comparator arms and trial interpretation, and response assessment after radiation is challenging.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Trastuzumab (Herceptin) | 2010 | First-line HER2-positive metastatic gastric/GEJ adenocarcinoma, +chemo | ToGA | Overall survival | Median OS 13.8 vs 11.1 months (HR 0.74) |
| Ramucirumab (Cyramza) | 2014 | Advanced gastric/GEJ adenocarcinoma after prior chemotherapy (mono or +paclitaxel) | REGARD / RAINBOW | Overall survival | RAINBOW median OS 9.6 vs 7.4 months (HR 0.81); REGARD 5.2 vs 3.8 months (HR 0.78) |
| Nivolumab (Opdivo) | 2021 | Adjuvant after neoadjuvant chemoradiation and resection with residual disease | CheckMate-577 | Disease-free survival | Median DFS 22.4 vs 11.0 months (HR 0.69) |
| Nivolumab (Opdivo) | 2021 | First-line advanced gastric/GEJ/oesophageal adenocarcinoma, +chemo | CheckMate-649 | Overall survival | CPS >= 5 median OS 14.4 vs 11.1 months (HR 0.71) |
| Pembrolizumab (Keytruda) | 2021 | First-line advanced/metastatic oesophageal (incl. GEJ) carcinoma, +chemo | KEYNOTE-590 | Overall survival | All-comers median OS 12.4 vs 9.8 months (HR 0.73); larger benefit in CPS >= 10 |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in oesophageal cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ramucirumab (first-line) — RAINFALL | Adding ramucirumab to first-line chemotherapy improved PFS marginally but failed to improve overall survival in metastatic gastric/GEJ adenocarcinoma | First-line anti-angiogenesis did not replicate its second-line benefit; modest PFS gain did not translate to survival |
| Cetuximab — EXPAND | Adding cetuximab to first-line chemotherapy did not improve progression-free or overall survival in advanced gastric/GEJ cancer and added toxicity | Unselected EGFR targeting without a predictive biomarker; gastroesophageal adenocarcinoma is not EGFR-driven in most patients |
Choosing the right endpoint
Primary endpoints that matter in oesophageal cancer trials
- Overall survival (OS) — Primary endpoint in ToGA, CheckMate-649 and KEYNOTE-590
- Disease-free survival (DFS) — Primary endpoint in the adjuvant CheckMate-577 trial
- Progression-free survival (PFS) — Common co-primary in first-line metastatic trials
- HER2 and PD-L1 (CPS) status — Key predictive biomarkers guiding trastuzumab and checkpoint-inhibitor use
- Pathologic complete response (pCR) — Endpoint in neoadjuvant chemoradiation trials informing perioperative strategy
How iNGENū runs oesophageal cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Oesophageal Cancer clinical trials — FAQs
How do treatments differ between squamous cell and adenocarcinoma oesophageal cancer?
What is the role of immunotherapy in oesophageal cancer?
Why is HER2 testing important?
Ready to discuss your oesophageal cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal